Diranersen

N/A

Report date: 2026/05/15 20:01:45
NME

Base Information

Drug NameDiranersen
Drug Alias NameBIIB-080ISIS-814907IONIS-MAPTRxISIS-BIIB4RxIONIS-BIIB4RX
ClassificationSmall molecules > Nucleosides and nucleotide derivtives > Oligonucleotide > Oligonucleotide antisense
Mechanisms of ActionMicrotubule-associated protein tau inhibitors
TargetsMicrotubule-associated protein tau
Therapy Area/IndicationsCognitive DysfunctionAlzheimer Disease
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryCzechiaBelgiumCanada +[17] 
CombinationsNo
Global Highest StatusPhase 2 Clinical
Highest Status in ChinaN/A
Originator CompaniesBiogen IncIonis Pharmaceuticals Inc
China Registration ClassN/A

Develop Information

Active CompaniesIonis Pharmaceuticals IncBiogen Inc
Inactive CompaniesN/A
Active IndicationsCognitive DysfunctionAlzheimer Disease
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A